Scriptaid and LBH589 synergize with Delta24-RGD oncolysis in patient-derived GSC cultures.

<p>(A) Chou Talalay assays were performed for Scriptaid (μM) and Delta24-RGD (MOI) to determine synergy in the GSCs GS102, GS224 and GS289. The treatments were added concomitantly to the cells. The results were depicted as viable fraction (0–100) compared to non-treated controls ± standard deviation for three replicates. *Indicates significant difference between combination and single agent treatments alone at p<0.05 level. (B) Chou Talalay assays were performed for LBH589 (nM) and Delta24-RGD (MOI) to determine synergy in the responsive GSCs GS102, GS224 and GS289. The treatments were added concomitantly to the cells. The results were depicted as viable fraction compared to non-treated controls ± standard deviation for three replicates. *Indicates significant difference between combination and single agent treatments alone at p<0.05 level. (C) The combination indices (CI) for both drugs and Delta24-RGD were calculated and shown in the same graph per GSC. A CI of < 1 indicates synergy between the two agents.